• Users Online: 186
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
This article has been cited by
1Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
Shashikant Sharma,Vishali Gupta,Aniruddha Maiti,Sribhargava Natesh,Sandeep Saxena,Vivek Dave,Vimal Parmar,Raju Sampangi,Hemanth Murthy,Sandhya Dharwadkar,Naresh Kumar Yadav,Shrinivas Joshi,Rahul Mayor,Dhanashree Ratra,Soumyava Basu,Neha Goel,Alok Chaturvedi,Ronak Patel,Vinu Jose
International Journal of Retina and Vitreous.2021;7(1)
[DOI]
2A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration
Shashikant Sharma,Mujtaba Khan,Alok Chaturvedi
Ophthalmology and Therapy.2020;9(1)103
[DOI]
3A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM
Alok Preethi B,Alok Shilpa G,Dhwani Anil Shah,Praveen R Murthy
Indian Journal of Clinical and Experimental Ophthalmology.2021;7(2)346
[DOI]
4A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
Shashikant Sharma,Manjunath Bhaskar Anandkumar,Sangita Jain,Hemanth Murthy,Naveenam Srinivasa Murlidhar,Raj Shri Hirawat,Aditya Sudhalkar,Amarendra Deka,Alay Banker,Vatsal Parikh,Manisha Agarwal,Charu Mithal,Rajender Pal Singh,Deepti Kulkarni,Abhishek Desai,Rushikesh Naigaonkar,Nishikant Borse,Simanta Pradeep Saikia,Atul Kumar Sahu,Shobhna Mange,Arup Chakraborty,Suprakash Roy,Valensha Surong,Mujtaba Khan,Alok Chaturvedi
Ophthalmology and Therapy.2020;9(3)625
[DOI]
5A Multinational Comparison of Anti–Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific
Ravi Parikh,Nathan Pirakitikulr,Jay Chhablani,Yoichi Sakurada,Rishi P. Singh,Yasha S. Modi
Ophthalmology Retina.2019;3(1)16
[DOI]
6Future of anti-VEGF: biosimilars and biobetters
Monika Kapur,Suvansh Nirula,Mayuresh P. Naik
International Journal of Retina and Vitreous.2022;8(1)16
[DOI]
7Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
Shashikant Sharma,Tanishq Sharma,Somdutt Prasad,Mahesh Gopalakrishnan,Alok Chaturvedi
Ophthalmology and Therapy.2021;10(3)431
[DOI]
8Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
Lalit Verma,Mithun Thulasidas,Ajay Purohit,Avnindra Gupta,Ritesh Narula,Dinesh Talwar
Indian Journal of Ophthalmology.2021;69(2)347
[DOI]